Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.99
VIVO's Cash-to-Debt is ranked lower than
66% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. VIVO: 0.99 )
Ranked among companies with meaningful Cash-to-Debt only.
VIVO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07  Med: 1 Max: No Debt
Current: 0.99
Equity-to-Asset 0.68
VIVO's Equity-to-Asset is ranked higher than
62% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. VIVO: 0.68 )
Ranked among companies with meaningful Equity-to-Asset only.
VIVO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.76 Max: 0.92
Current: 0.68
0.35
0.92
Debt-to-Equity 0.33
VIVO's Debt-to-Equity is ranked lower than
52% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.31 vs. VIVO: 0.33 )
Ranked among companies with meaningful Debt-to-Equity only.
VIVO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.61 Max: 1.41
Current: 0.33
0.01
1.41
Interest Coverage 22.50
VIVO's Interest Coverage is ranked lower than
57% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.16 vs. VIVO: 22.50 )
Ranked among companies with meaningful Interest Coverage only.
VIVO' s Interest Coverage Range Over the Past 10 Years
Min: 22.5  Med: No Debt Max: No Debt
Current: 22.5
Piotroski F-Score: 5
Altman Z-Score: 6.72
Beneish M-Score: -3.07
WACC vs ROIC
5.39%
12.41%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 18.92
VIVO's Operating Margin % is ranked higher than
93% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.05 vs. VIVO: 18.92 )
Ranked among companies with meaningful Operating Margin % only.
VIVO' s Operating Margin % Range Over the Past 10 Years
Min: 18.92  Med: 28.66 Max: 32.9
Current: 18.92
18.92
32.9
Net Margin % 10.76
VIVO's Net Margin % is ranked higher than
90% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.21 vs. VIVO: 10.76 )
Ranked among companies with meaningful Net Margin % only.
VIVO' s Net Margin % Range Over the Past 10 Years
Min: 10.76  Med: 18.98 Max: 22.09
Current: 10.76
10.76
22.09
ROE % 12.70
VIVO's ROE % is ranked higher than
83% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.23 vs. VIVO: 12.70 )
Ranked among companies with meaningful ROE % only.
VIVO' s ROE % Range Over the Past 10 Years
Min: 12.7  Med: 22.86 Max: 25.78
Current: 12.7
12.7
25.78
ROA % 8.50
VIVO's ROA % is ranked higher than
88% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.45 vs. VIVO: 8.50 )
Ranked among companies with meaningful ROA % only.
VIVO' s ROA % Range Over the Past 10 Years
Min: 8.5  Med: 20.4 Max: 22.5
Current: 8.5
8.5
22.5
ROC (Joel Greenblatt) % 42.16
VIVO's ROC (Joel Greenblatt) % is ranked higher than
82% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. VIVO: 42.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
VIVO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 42.16  Med: 67.18 Max: 89.27
Current: 42.16
42.16
89.27
3-Year Revenue Growth Rate 0.90
VIVO's 3-Year Revenue Growth Rate is ranked lower than
65% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.50 vs. VIVO: 0.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
VIVO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0.9  Med: 10.4 Max: 25
Current: 0.9
0.9
25
3-Year EBITDA Growth Rate -3.00
VIVO's 3-Year EBITDA Growth Rate is ranked lower than
65% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. VIVO: -3.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
VIVO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -3  Med: 15.7 Max: 67.4
Current: -3
-3
67.4
3-Year EPS without NRI Growth Rate -5.80
VIVO's 3-Year EPS without NRI Growth Rate is ranked lower than
59% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. VIVO: -5.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
VIVO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -27.1  Med: 20.3 Max: 64.6
Current: -5.8
-27.1
64.6
GuruFocus has detected 4 Warning Signs with Meridian Bioscience Inc $VIVO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» VIVO's 30-Y Financials

Financials (Next Earnings Date: 2017-11-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

VIVO Guru Trades in Q3 2016

Jim Simons 1,914,676 sh (+8.72%)
Keeley Asset Management Corp 82,375 sh (unchged)
Mario Gabelli 140,000 sh (unchged)
Chuck Royce 48,300 sh (unchged)
Joel Greenblatt 246,898 sh (-6.57%)
Paul Tudor Jones 27,903 sh (-31.88%)
» More
Q4 2016

VIVO Guru Trades in Q4 2016

Discovery Group I, LLC 340,282 sh (New)
Chuck Royce 116,928 sh (+142.09%)
Mario Gabelli 140,000 sh (unchged)
Keeley Asset Management Corp Sold Out
Jim Simons 1,873,200 sh (-2.17%)
Joel Greenblatt 211,281 sh (-14.43%)
Paul Tudor Jones 21,515 sh (-22.89%)
» More
Q1 2017

VIVO Guru Trades in Q1 2017

Barrow, Hanley, Mewhinney & Strauss 7,605 sh (New)
Paul Tudor Jones 49,868 sh (+131.78%)
Chuck Royce 157,894 sh (+35.04%)
Mario Gabelli 175,000 sh (+25.00%)
Joel Greenblatt 234,281 sh (+10.89%)
Jim Simons 1,988,276 sh (+6.14%)
Discovery Group I, LLC Sold Out
» More
Q2 2017

VIVO Guru Trades in Q2 2017

Leucadia National 12,513 sh (New)
Barrow, Hanley, Mewhinney & Strauss 150,141 sh (+1874.24%)
Chuck Royce 157,894 sh (unchged)
Mario Gabelli 175,000 sh (unchged)
Jim Simons 1,967,300 sh (-1.05%)
Joel Greenblatt 214,227 sh (-8.56%)
Paul Tudor Jones 32,223 sh (-35.38%)
» More
» Details

Insider Trades

Latest Guru Trades with VIVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-06-30 Reduce -8.56%$13.1 - $15.95 $ 14.20-1%214,227
Barrow, Hanley, Mewhinney & Strauss 2017-06-30 Add 1874.24%$13.1 - $15.95 $ 14.20-1%150,141
Leucadia National 2017-06-30 New Buy0.02%$13.1 - $15.95 $ 14.20-1%12,513
Joel Greenblatt 2017-03-31 Add 10.89%$12.2 - $17.85 $ 14.202%234,281
Mario Gabelli 2017-03-31 Add 25.00%$12.2 - $17.85 $ 14.202%175,000
Barrow, Hanley, Mewhinney & Strauss 2017-03-31 New Buy$12.2 - $17.85 $ 14.202%7,605
Joel Greenblatt 2016-12-31 Reduce -14.43%0.01%$15.9 - $19.5 $ 14.20-19%211,281
Keeley Asset Management Corp 2016-12-31 Sold Out 0.07%$15.9 - $19.5 $ 14.20-19%0
Joel Greenblatt 2016-09-30 Reduce -6.57%$18.94 - $20.48 $ 14.20-27%246,898
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 2835
Compare:NAS:PACB, NAS:LNTH, NAS:RDNT, NAS:HSKA, NYSE:ENZ, NAS:NTRA, NYSE:ARA, NYSE:NVTA, AMEX:SENS, NAS:SRDX, NAS:NEO, NAS:NRCIB, NAS:ALOG, NAS:ONVO, NAS:FLDM, NAS:MGEN, NAS:ABAX, LSE:MXCR, NAS:CTSO, NAS:AIQ » details
Traded in other countries:MR4.Germany,
Headquarter Location:USA
Meridian Bioscience Inc is an integrated life science company. It is engaged in development, manufacture, sale and distribution of diagnostic test kits for certain gastrointestinal, viral, respiratory and parasitic infectious diseases.

Meridian Bioscience Inc was incorporated in Ohio in 1976. The Company is an integrated life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for certain gastrointestinal, viral, respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers; and the contract development and manufacture of proteins and other biologicals under cGMP conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. Its segments are Diagnostics and Life Science. The Diagnostics segment consists of manufacturing operations in Cincinnati, Ohio, and the sale and distribution of diagnostic test kits in the countries comprising North, Central and South America (the Americas); Europe, Middle East and Africa (EMEA); and other countries outside of the Americas and EMEA (rest of the world, or ROW). In the Diagnostics Segment, its testing platforms include: Isothermal DNA Amplification (illumigene brand); Rapid Immunoassay (TRU, ImmunoCard and ImmunoCard STAT! brands); and Enzyme-linked Immunoassay ( Premier brand). Its product portfolio includes over 140 diagnostic tests and transport media, and is marketed to acute care hospitals, reference laboratories and outpatient clinics in over 70 countries around the world. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany; and Sydney, Australia, and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents domestically and abroad, including sales and business development offices in Singapore and Beijing, China. The Life Science segment also includes the contract development and manufacture of cGMP clinical grade proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

Ratios

vs
industry
vs
history
PE Ratio 27.85
VIVO's PE Ratio is ranked higher than
72% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.78 vs. VIVO: 27.85 )
Ranked among companies with meaningful PE Ratio only.
VIVO' s PE Ratio Range Over the Past 10 Years
Min: 18.07  Med: 25.97 Max: 48.49
Current: 27.85
18.07
48.49
Forward PE Ratio 21.83
VIVO's Forward PE Ratio is ranked higher than
66% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.92 vs. VIVO: 21.83 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 27.85
VIVO's PE Ratio without NRI is ranked higher than
73% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 38.46 vs. VIVO: 27.85 )
Ranked among companies with meaningful PE Ratio without NRI only.
VIVO' s PE Ratio without NRI Range Over the Past 10 Years
Min: 18.07  Med: 25.97 Max: 48.28
Current: 27.85
18.07
48.28
Price-to-Owner-Earnings 20.21
VIVO's Price-to-Owner-Earnings is ranked higher than
76% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.54 vs. VIVO: 20.21 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
VIVO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 14.91  Med: 30.11 Max: 68.13
Current: 20.21
14.91
68.13
PB Ratio 3.58
VIVO's PB Ratio is ranked higher than
50% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. VIVO: 3.58 )
Ranked among companies with meaningful PB Ratio only.
VIVO' s PB Ratio Range Over the Past 10 Years
Min: 3.19  Med: 5.8 Max: 11.73
Current: 3.58
3.19
11.73
PS Ratio 3.03
VIVO's PS Ratio is ranked higher than
54% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. VIVO: 3.03 )
Ranked among companies with meaningful PS Ratio only.
VIVO' s PS Ratio Range Over the Past 10 Years
Min: 2.74  Med: 5.02 Max: 10.96
Current: 3.03
2.74
10.96
Price-to-Free-Cash-Flow 15.48
VIVO's Price-to-Free-Cash-Flow is ranked higher than
73% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.07 vs. VIVO: 15.48 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
VIVO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 14.01  Med: 28.79 Max: 70.85
Current: 15.48
14.01
70.85
Price-to-Operating-Cash-Flow 13.83
VIVO's Price-to-Operating-Cash-Flow is ranked higher than
67% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.14 vs. VIVO: 13.83 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
VIVO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 12.5  Med: 23.91 Max: 49.75
Current: 13.83
12.5
49.75
EV-to-EBIT 15.72
VIVO's EV-to-EBIT is ranked higher than
81% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. VIVO: 15.72 )
Ranked among companies with meaningful EV-to-EBIT only.
VIVO' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.4  Med: 16.5 Max: 35.7
Current: 15.72
11.4
35.7
EV-to-EBITDA 12.99
VIVO's EV-to-EBITDA is ranked higher than
75% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.58 vs. VIVO: 12.99 )
Ranked among companies with meaningful EV-to-EBITDA only.
VIVO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.9  Med: 14.8 Max: 31.9
Current: 12.99
9.9
31.9
EV-to-Revenue 3.02
VIVO's EV-to-Revenue is ranked higher than
59% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. VIVO: 3.02 )
Ranked among companies with meaningful EV-to-Revenue only.
VIVO' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.8  Med: 4.8 Max: 10.6
Current: 3.02
2.8
10.6
PEG Ratio 7.26
VIVO's PEG Ratio is ranked lower than
73% of the 48 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.20 vs. VIVO: 7.26 )
Ranked among companies with meaningful PEG Ratio only.
VIVO' s PEG Ratio Range Over the Past 10 Years
Min: 0.98  Med: 3.56 Max: 24.82
Current: 7.26
0.98
24.82
Shiller PE Ratio 17.47
VIVO's Shiller PE Ratio is ranked higher than
87% of the 31 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 47.44 vs. VIVO: 17.47 )
Ranked among companies with meaningful Shiller PE Ratio only.
VIVO' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.43  Med: 34.55 Max: 137.12
Current: 17.47
15.43
137.12
Current Ratio 6.47
VIVO's Current Ratio is ranked higher than
81% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. VIVO: 6.47 )
Ranked among companies with meaningful Current Ratio only.
VIVO' s Current Ratio Range Over the Past 10 Years
Min: 1.4  Med: 5.44 Max: 11.4
Current: 6.47
1.4
11.4
Quick Ratio 4.42
VIVO's Quick Ratio is ranked higher than
73% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. VIVO: 4.42 )
Ranked among companies with meaningful Quick Ratio only.
VIVO' s Quick Ratio Range Over the Past 10 Years
Min: 0.87  Med: 3.8 Max: 9.6
Current: 4.42
0.87
9.6
Days Inventory 213.06
VIVO's Days Inventory is ranked lower than
91% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.72 vs. VIVO: 213.06 )
Ranked among companies with meaningful Days Inventory only.
VIVO' s Days Inventory Range Over the Past 10 Years
Min: 130.86  Med: 178.85 Max: 216.11
Current: 213.06
130.86
216.11
Days Sales Outstanding 51.10
VIVO's Days Sales Outstanding is ranked higher than
67% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.84 vs. VIVO: 51.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
VIVO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.91  Med: 53.72 Max: 67.24
Current: 51.1
44.91
67.24
Days Payable 29.08
VIVO's Days Payable is ranked lower than
75% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.91 vs. VIVO: 29.08 )
Ranked among companies with meaningful Days Payable only.
VIVO' s Days Payable Range Over the Past 10 Years
Min: 25.32  Med: 33.24 Max: 45.39
Current: 29.08
25.32
45.39

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 4.05
VIVO's Dividend Yield % is ranked higher than
92% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. VIVO: 4.05 )
Ranked among companies with meaningful Dividend Yield % only.
VIVO' s Dividend Yield % Range Over the Past 10 Years
Min: 1.24  Med: 3.58 Max: 6.32
Current: 4.05
1.24
6.32
Dividend Payout Ratio 1.30
VIVO's Dividend Payout Ratio is ranked lower than
86% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.34 vs. VIVO: 1.30 )
Ranked among companies with meaningful Dividend Payout Ratio only.
VIVO' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.61  Med: 0.95 Max: 1.3
Current: 1.3
0.61
1.3
3-Year Dividend Growth Rate 1.70
VIVO's 3-Year Dividend Growth Rate is ranked lower than
65% of the 34 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. VIVO: 1.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
VIVO' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 14 Max: 69.4
Current: 1.7
0
69.4
Forward Dividend Yield % 3.52
VIVO's Forward Dividend Yield % is ranked higher than
84% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.11 vs. VIVO: 3.52 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.32
VIVO's 5-Year Yield-on-Cost % is ranked higher than
84% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.46 vs. VIVO: 4.32 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
VIVO' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.32  Med: 3.82 Max: 6.74
Current: 4.32
1.32
6.74
3-Year Average Share Buyback Ratio -0.50
VIVO's 3-Year Average Share Buyback Ratio is ranked higher than
76% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. VIVO: -0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
VIVO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -6.3  Med: -0.7 Max: 0
Current: -0.5
-6.3
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 11.64
VIVO's Price-to-Net-Current-Asset-Value is ranked lower than
61% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.24 vs. VIVO: 11.64 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
VIVO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.65  Med: 11.57 Max: 65
Current: 11.64
2.65
65
Price-to-Tangible-Book 7.03
VIVO's Price-to-Tangible-Book is ranked lower than
69% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.17 vs. VIVO: 7.03 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
VIVO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.73  Med: 8.58 Max: 24.67
Current: 7.03
1.73
24.67
Price-to-Intrinsic-Value-Projected-FCF 1.27
VIVO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
77% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.25 vs. VIVO: 1.27 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
VIVO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.54  Med: 2.56 Max: 6.42
Current: 1.27
0.54
6.42
Price-to-Intrinsic-Value-DCF (Earnings Based) 2.60
VIVO's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
50% of the 18 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.07 vs. VIVO: 2.60 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
VIVO' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.64  Med: 1.26 Max: 2.91
Current: 2.6
0.64
2.91
Price-to-Median-PS-Value 0.61
VIVO's Price-to-Median-PS-Value is ranked higher than
77% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. VIVO: 0.61 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
VIVO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.13  Med: 0.79 Max: 2.05
Current: 0.61
0.13
2.05
Price-to-Graham-Number 2.95
VIVO's Price-to-Graham-Number is ranked higher than
59% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.54 vs. VIVO: 2.95 )
Ranked among companies with meaningful Price-to-Graham-Number only.
VIVO' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.23  Med: 3.33 Max: 6.32
Current: 2.95
1.23
6.32
Earnings Yield (Greenblatt) % 6.38
VIVO's Earnings Yield (Greenblatt) % is ranked higher than
90% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.04 vs. VIVO: 6.38 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
VIVO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.8  Med: 6.1 Max: 8.8
Current: 6.38
2.8
8.8
Forward Rate of Return (Yacktman) % 4.96
VIVO's Forward Rate of Return (Yacktman) % is ranked lower than
52% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.57 vs. VIVO: 4.96 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
VIVO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 4.3  Med: 10.5 Max: 26.8
Current: 4.96
4.3
26.8

More Statistics

Revenue (TTM) (Mil) $198.07
EPS (TTM) $ 0.51
Beta0.56
Short Percentage of Float11.52%
52-Week Range $10.75 - 19.85
Shares Outstanding (Mil)42.20

Analyst Estimate

Sep17 Sep18
Revenue (Mil $) 198 202
EPS ($) 0.73 0.65
EPS without NRI ($) 0.73 0.65
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for VIVO

Headlines

Articles On GuruFocus.com
Meridian Contributes to Upcoming “LEADCON 2017” – Third Annual International Conferen Sep 19 2017 
Meridian Launches TRU Block® ULTRA – A Powerful Immunoassay Interference Blocker Sep 05 2017 
Meridian Initiates Clinical Trials for New Neonatal Saliva CMV illumigene Test Aug 09 2017 
Meridian Bioscience Introduces the Expansion of Its ImmunoCard STAT!® Product Line Aug 08 2017 
Meridian Bioscience Elects John Rice to the Board of Directors Aug 08 2017 
Bioline Launches New JetSeq™ Clean Kit for Next-Generation Sequencing Aug 02 2017 
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Meridian Bioscience, Inc Jul 26 2017 
Meridian Announces Wholly Foreign Owned Enterprise (WFOE) Office in Beijing, China Jul 20 2017 
MERIDIAN BIOSCIENCE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Ex Jul 13 2017 
Meridian Bioscience Comments on Recent FDA Press Statement Jul 13 2017 

More From Other Websites
Meridian Contributes to Upcoming “LEADCON 2017” – Third Annual International Conference on the... Sep 19 2017
Meridian Bioscience, Inc. breached its 50 day moving average in a Bullish Manner : VIVO-US :... Sep 14 2017
Meridian Launches TRU Block® ULTRA – A Powerful Immunoassay Interference Blocker Sep 05 2017
ETFs with exposure to Meridian Bioscience, Inc. : August 28, 2017 Aug 28 2017
Meridian Bioscience, Inc. :VIVO-US: Earnings Analysis: Q3, 2017 By the Numbers : August 21, 2017 Aug 21 2017
Meridian (VIVO) Initiates illumigene CMV Trial, Shares Shine Aug 10 2017
Meridian Initiates Clinical Trials for New Neonatal Saliva CMV illumigene Test Aug 09 2017
Meridian Bioscience, Inc. – Value Analysis (NASDAQ:VIVO) : August 8, 2017 Aug 08 2017
Meridian Bioscience Introduces the Expansion of Its ImmunoCard STAT!® Product Line Aug 08 2017
Meridian Bioscience Elects John Rice to the Board of Directors Aug 08 2017
Bioline Launches New JetSeq™ Clean Kit for Next-Generation Sequencing Aug 02 2017
Meridian Bioscience meets 3Q profit forecasts Jul 27 2017
Meridian Bioscience, Inc. breached its 50 day moving average in a Bearish Manner : VIVO-US : July... Jul 27 2017
Meridian Bioscience Reports Third Fiscal Quarter 2017 Operating Results, Including Non-Cash Goodwill... Jul 27 2017
The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal... Jul 26 2017
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Meridian Bioscience,... Jul 26 2017
Meridian Announces Wholly Foreign Owned Enterprise (WFOE) Office in Beijing, China Jul 20 2017
MERIDIAN BIOSCIENCE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses... Jul 13 2017
VIVO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation... Jul 13 2017
FDA raises concerns about Meridian's plant that makes lead tests Jul 13 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}